GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Science 37 Holdings Inc (NAS:SNCE) » Definitions » Float Percentage Of Total Shares Outstanding

Science 37 Holdings (Science 37 Holdings) Float Percentage Of Total Shares Outstanding : 56.53% (As of Jun. 01, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Science 37 Holdings Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Science 37 Holdings's float shares is 3.41 Mil. Science 37 Holdings's total shares outstanding is 6.03 Mil. Science 37 Holdings's float percentage of total shares outstanding is 56.53%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Science 37 Holdings's Insider Ownership is 99.35%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Science 37 Holdings's Institutional Ownership is 6.65%.


Science 37 Holdings Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Science 37 Holdings's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=3.41/6.03
=56.53%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Science 37 Holdings (Science 37 Holdings) Business Description

Traded in Other Exchanges
N/A
Address
800 Park Offices Drive, Suite 3606, Research Triangle Park, Durham, NC, USA, 27709
Science 37 Holdings Inc is engaged in the development of new and innovative treatments that impact patient lives. It enables universal access to patients and providers for clinical trials. Its Operating System is fused with networks of telemedicine investigators, mobile nurses, remote coordinators, patient communities and connected devices.
Executives
Troy Bryenton officer: Chief Technology Officer 800 PARK OFFICES DRIVE, SUITE 3606, RESEARCH TRIANGLE PARK NC 27709
Christine A Pellizzari officer: Chief Legal Officer 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Autenried Paul Von director BRISTOL-MYERS SQUIBB COMPANY, 100 NASSAU PARK BOULEVARD, PRINCETON NJ 08543
Michael Shipton officer: Chief Commercial Officer 800 PARK OFFICES DRIVE SUITE 3606, RESEARCH TRIANGLE PARK NC 27709
Adam Goulburn director C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Thermo Fisher Scientific Powder Us Holdings Corp. 10 percent owner 168 THIRD AVENUE, WALTHAM MA 02451
Thermo Fisher Scientific Inc. 10 percent owner 168 THIRD AVENUE, WALTHAM MA 02451
Neil Tiwari director C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Darcy Forman officer: Chief Delivery Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
David Coman director, officer: Chief Executive Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Jonathan Cotliar officer: Chief Medical Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Steven Geffon officer: Chief Commercial Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
De Silva Bhooshitha B. director PPD, INC., 929 NORTH FRONT STREET, WILMINGTON NC 28401
Mike Zaranek officer: Chief Financial Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Ppd, Inc. 10 percent owner 929 NORTH FRONT STREET, WILMINGTON NC 28401-3331